Débat - ARCAGY

!"#$%##"&'#(#%)(*+,$-(!-#(./-),*"-#($"0+--#(-.($,'$-)#(!-(+1&2,")-((
(
(
Recommandations,de,l’utilisation,de,l’Avastin,en,première,ligne,
 Question):)pour)les)stades)IIIC,)comment)prévoir)avant)un)traitement)par)
chimiothérapie)que)dans)6)cycles)de)traitement)la)maladie)sera)toujours)non)
résécable)?((
(
"3(4(565(78979:5(;(<(Situations,où,le,bevacizumab,est,recommandé(;(
( (=)5:>?@(6@A9843(A4B89:B97>C@D(478E:(BF>8@8G>D(?D(BH69=85?@B6>9I(>I>6>43D(79@8(3D:(:64?D:(
(((((J"K&("""0(L("2M(
( =(#64?D("""$="2(?5N>I>6>ODADI6(I9I(85:5B4P3D(?D(N4Q9I(B9A73E6DM+D(B484B6E8D(?5N>I>6>ODADI6(
((((I9I(85:5B4P3D(?D:(35:>9I:(?9>6(R68D(S@G5(DI()$*(DI(785:DIBD(?1@ID(5C@>7D(BF>8@8G>B43D(
( DI684TI5DM(
(
)579I:D(?D:(DU7D86:(;("3(D:6(O84>(C@D(3D:(B4:(9V(319I(S@GD(3D(B4IBD8(I9I(85:5B4P3D(?E:(3D(?57486(:9I6(
848D:(564I6(?9II5(34(BF>A>9:DI:>P>3>65(?4I:(3D(B4IBD8(?D(319O4>8D(W748(DU(;(:@SD6(68E:(XG5(4ODB(
B9A98P>?>65:Y(75?>B@3D(F5746>C@DY(DIO4F>::DADI6(?@(B488DN9@8Z[M(+15O43@46>9I(>I>6>43D(D:6(D::DI6>D33D(
79@8(>?DI6>N>D8(BD:(B4:M(
+4(789P35A46>C@D(DI()$*(7D@6(R68D(DNNDB6>ODADI6(?D(ID(74:(AD668D(,O4:6>I(L(@ID(746>DI6D(?E:(3D(
?57486(D6(?D(:147D8BDO9>8(4@(P9@6(?D(\(BHB3D:(C@1D33D(D:6(69@S9@8:(I9I(85:5B4P3D(](9I(4(?4I:(BD66D(
:>6@46>9I(@ID(7D86D(?D(BF4IBD(79@8(34(746>DI6DM(
$1D:6(79@8(BD66D(84>:9I(C@D(3D:(8DB9AA4I?46>9I:(I19I6(74:(DUB3@(31,O4:6>I(DI(:>6@46>9I(79:6=BF>8@8G>D(
?1>I6D8O433DY(ARAD(:>(BD(I1D:6(74:(S@:6>N>5(?>8DB6DADI6(748(3D:(D::4>:M(-I(DNND6(:>(9I(8DB9AA4I?4>6(?D(
ID(74:(N4>8D(?D(31,O4:6>I(478E:(34(BF>8@8G>D(?1>I6D8O433DY(9I(:D84>6(9P3>G5(79@8(BD:(746>DI6D:(?D(A4@O4>:(
789I9:6>B(?D(N4>8D(@I(BF9>U(DI68D(^(6F5847D@6>C@D:(DNN>B4BD:(BF>8@8G>D(?1>I6D8O433D(D6(,O4:6>IY(BD(C@>(
I14(74:(?D(:DI:M(*9@8(34(73@7486(?D:(746>DI6D:(9V(31DNN986(A4U>A@A(L(O>:5D(?1DU58E:D(B9A73E6D(ID(
7D@6(R68D(N4>6(>I>6>43DADI6(D6(C@1>3(D:6(734I>N>5(398:(?1@ID(BF>8@8G>D(?1>I6D8O433DY(9I(N4>6(_(BHB3D:(?D(
BF>A>96F5847>DY(7@>:(@ID(BF>8@8G>D(:>(79::>P3D(D6(31,O4:6>I(D:6(?>:B@65(L(BD(A9ADI6=3LM(
(
 Question):)Les)stades)III‐)IV)en)exérèse)complète)font)partie)de)l’AMM.)Pourquoi)ne)pas)
recommander)l’Avastin)dans)cette)situation)?(
)
"3(4(565(78979:5(;(<(#>6@46>9I:(9V(3D(bevacizumab,est,à,évaluer,en,RCP,et,à,discuter,avec,la,patiente,
en,fonction,du,rapport,bénéfice/,risque`;(
( (=(#64?D:("""0(9@("""$(4ODB(DU58E:D(A4B89:B97>C@DADI6(B9A73E6D((398:(?D(34(BF>8@8G>D(>I>6>43DM(
( =(,78E:(BF>8@8G>D(?1>I6D8O433D(478E:(_(9@(a(BHB3D:(?D(BF>A>96F5847>D(I59=4?S@O4I6D(
`78DI4I6(DI(B9A76D(I964AADI6(3D:(4I65B5?DI6:(I57F89=B48?>9=O4:B@34>8D:(D6(34(8543>:46>9I(
?14I4:69A9:D:(?>GD:6>OD:(398:(?D(34(BF>8@8G>D(>I>6>43D(9@(69@6(8>:C@D(?D(N>:6@3DM(
(
)579I:D(?D:(DU7D86:(;("3(I1DU>:6D(74:(?D(?9II5D:(?1DNN>B4B>65(?@(PDO4B>b@A4P(BFDb(BD:(746>DI6D:(DI(
DU58E:D(B9A73E6D(BF>8@8G>B43DM(+1D::4>(K&K^cd(I1>IB3@4>6(C@D(?D:(746>DI6D:(4ODB(85:>?@:(

A4B89:B97>C@D:M($D(I1D:6(C@D(?4I:(31D::4>("$&'e(C@D(BD:(746>DI6D:(9I6(565(>IB3@D:(?4I:(@ID(4I43H:D(
?D(:9@:=G89@7D(C@>(ID(8D689@OD(74:(?4I:(3D(:9@:=G89@7D(?D:(746>DI6D:(DI(DU58E:D(
A4B89:B97>C@DADI6(B9A73E6D(9@(35:>9I:((f(c(BAY(?D(P5I5N>BD(?D(314??>6>9I(?@(PDO4B>b@A4P(64I6(DI(
*J#(C@1DI(:@8O>D(G39P43D(M((
*D@6=R68D(BD66D(4P:DIBD(?D(P5I5N>BD(D:6(3>5D(L(314P:DIBD(?D(8DB@3(?D:(D::4>:M(*D@6=R68D(C@D(3D(
PDO4B>b@A4P(C@>(:DAP3D(BH69:646>C@D(I1D:6(DNN>B4BD(C@D(:@8(3D:(8DBF@6D:(?DO4I6(:@8ODI>8(4@(B9@8:(?D((
:9I(4?A>I>:6846>9IM(&8(BD66D(797@346>9I(4ODB(DU58E:D(BF>8@8G>B43D(B9A73E6D(D:6(8DB9II@D(B9AAD(?D(
P9I(789I9:6>B(4ODB(@I(64@U(?D(85B>?>OD(L(c(4I(:D@3DADI6(?D(3198?8D(?D((^ghM($D66D(FH796FE:D(D:6(
8DIN98B5D(748(319P:D8O46>9I(?1@I(BFDO4@BFDADI6(?D:(B9@8PD:(?D(:@8O>D(:4I:(789G8D::>9I(4@=?D3L(?D(
?D@U(4I:Y(A9I684I6(@ID(7D86D(?1DNN>B4B>65(L(31488R6(?@(684>6DADI6(748(PDO4B>b@A4PM((
!4I:(BD(B4:Y(>3(N4@?84>6(>?DI6>N>D8(3D:(746>DI6D:(C@>(:9I6(3D(73@:(L(8>:C@D(?D(8DBF@6D(785B9BD(478E:(
DU58E:D(B9A73E6D(BF>8@8G>B43DM(&I(7D@6(7DI:D8(C@D(3D(8>:C@D(D:6(73@:(>A79864I6(:>(31DU58E:D(B9A73E6D(
D:6(9P6DI@D(478E:(@ID(>I6D8ODI6>9I(34P98>D@:D(4ODB(?D:(:4B8>N>BD:(?198G4ID(C@D(79@8(@I(:64?D("""(
B9A79864I6(@I(:D@3(I9?@3D(:@8(3D(G84I?(57>7399IM(i4>:(I9@:(I14O9I:(74:(?D(B8>6E8D:(9PSDB6>N:(O43>?5:(
L(BD(S9@8M(
!9IB(B1D:6(:@8(34(785:DIBD(?D(85:>?@(C@19I(4::9>6(3D:(8DB9AA4I?46>9I:(79@8(31,O4:6>I(DI(78DA>E8D(
3>GID(?D(B4IBD8(?D(319O4>8D(D6(P>DI(:j8(?@(6D884>I(?D(34(746>DI6D(WB9A98P>?>65:[(
c((*D88DI(.kY(D6(43M(,(7F4:D(_(68>43(9N(PDO4B>b@A4P(>I(9O48>4I(B4IBD8M('(-IG3(k(iD?M(^gcc]_\lW^\[;^ada=m\(
c(0@8GD8(),Y(D6(43M("IB9879846>9I(9N(PDO4B>b@A4P(>I(6FD(78>A48H(68D46ADI6(9N(9O48>4I(B4IBD8M('(-IG3(k(iD?M(
^gcc]_\lW^\[;^ae_=d_M(
(
(
La,chimiothérapie,associée,à,l’Avastin,en,première,ligne,
(
 Question):)en)situation)de)1religne,)les)recommandations)n’ont)pas)évalué)l’intérêt)du)schéma)
dose‐dense.)Sur)quels)arguments)faut‐il)préférer)une)chimiothérapie)toutes)les)3)semaines)
associée)à)Avastin)plutôt)qu’un)schéma)dose‐dense)?)(
+4(:>6@46>9I(?@(?9:D=?DI:D(8D:6D(?5P466@DM(+4(:@758>98>65(?1DNN>B4B>65(?@(?9:D=?DI:D(W74B3>64UD3(
FDP?9A4?4>8D(n(B48P97346>ID(69@6D:(_(:DA4>ID:[(4(565(A9I685D(BFDb(3D:(S479I4>:Y(A4>:(4ODB(?4I:(
BD66D(797@346>9I(@I(DUBE:(?D(69U>B>65(C@>(N4>6(C@D(BD(85G>AD(I1D:6(74:(47789@O5(4@(k479I(ARADM((
$FDb(3D:($4@B4:>DI:Y(?9I6(3D(A564P93>:AD(?D:(64U4ID:(D:6(?>NN58DI6Y(34(69U>B>65(?@(?9:D=?DI:D(D:6(4@(
B9I684>8D(69@6(L(N4>6(4BBD764P3D(D6(31D::4>(&B64O>4(A9I68D(C@D(319I(7D@6(4S9@6D8(31,O4:6>I(:4I:(:9@B>M(
i4>:(H(4=6=>3(@I(P5I5N>BD(4@(?9:D=?DI:D(BFDb(3D:(B4@B4:>DI:(o($D66D(C@D:6>9I(N4>6(319PSD6(?D(I9AP8D@U(
D::4>:(DI(B9@8:(WH(B9A78>:(DI(J84IBD(3D(i".&e(4ODB(3D:("643>DI:[(